NantKwest stock: buy or sell?
January 17th, 2020
NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States.
Should I buy NantKwest stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to choose your own trading plan that matches with your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with NantKwest stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is NantKwest stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for NK stock for the last month.
NantKwest stock analysis
After boosting an astounding 28.18% on January 16th, NantKwest closed yesterday at $7.35 and declined a bad -0.41%.
After boosting an astounding 28.18% on January/16, NantKwest closed yesterday at $7.35 and declined a bad -0.41%. Since price and SMA200d lines crossed up on November, NK climbed $6.17 (522.88%). Since SMA100d and SMA200d crossed up on November, NK price climbed $6.30 per share (600.00%).
After sliding a chilling -13.48% in a week last week, NantKwest closed this week at $7.35 and skyrocketed an exceptional 106.46%.
NantKwest stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Since price and SMA40w lines crossed up by mid November 2019, NK climbed $6.25 (568.18%). Late October 2019, SMA20w and SMA40w crossed up triggering a rise of 533.62%.
NantKwest stock price history
NantKwest IPO was on September 2nd, 2014 at $0.02 per share1. Since then, NK stock surged a 36,650.00%, with a yearly average of 7,330.00%. If you had invested $1,000 in NantKwest stock in 2014, it would worth $366,500.00 today.
1: Adjusted price after possible price splits or reverse-splits.
NantKwest stock historical price chart
NK stock reached 52-week highs on Jan/16 at $9.90, and all-time highs 2015-07-28 with a price of 38.48.
NantKwest stock price targetHow much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' NK stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not detected any price target for NantKwest stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareSince last April, when NantKwest posted its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, NantKwest annual revenues raised a beatiful 4.44% to $0.05 M dollars from $0.05 marked in 2017. When comparing 2018 vs 2017, slightly better, profit margin (that is, the net income divided by revenues) skyrocketed a 9,537.16% to -204,736.17%.
|2013||$0.60 M||-||$-2.05 M-341.7%||-|
|2014||$0.64 M||6.83%||$-6.21 M-969.3%||203.07%|
|2015||$0.24 M||-63.18%||$-236.88 M-100371.2%||3,712.59%|
|2016||$0.04 M||-81.36%||$-120.81 M-274565.9%||-49.00%|
|2017||$0.05 M||2.27%||$-96.42 M-214273.3%||-20.19%|
|2018||$0.05 M||4.44%||$-96.23 M-204736.2%||-0.20%|
Quarterly financial resultsNantKwest posted $0.01 million in sales for 2018-Q4, a -77.42% less compared to previous quarter. Reported quarter earnings marked $-17.34 million with a profit margin of -247,714.29%. Profit margin collapsed a -171,472.35% compared to previous quarter when profit margin was -76,241.94%. When comparing sales to same quarter last year, NantKwest sales marked a frightening slide and plummed a -41.67%.
|2017-Q1||$0.01 M||-||$-24.52 M-222909.1%||-|
|2017-Q2||$0.01 M||27.27%||$-23.45 M-167500.0%||-4.36%|
|2017-Q3||$0.01 M||-42.86%||$-23.97 M-299612.5%||2.21%|
|2017-Q4||$0.01 M||50.00%||$-24.49 M-204058.3%||2.16%|
|2018-Q1||$0.01 M||-58.33%||$-27.52 M-550380.0%||12.38%|
|2018-Q2||$0.00 M||-20.00%||$-27.73 M-693300.0%||0.77%|
|2018-Q3||$0.03 M||675.00%||$-23.64 M-76241.9%||-14.77%|
|2018-Q4||$0.01 M||-77.42%||$-17.34 M-247714.3%||-26.63%|
NantKwest ownershipWhen you are planning to invest in shares of a stock, it's always worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For NantKwest, 71.81% of all outstanding shares are owned by its staff.
In case of NantKwest stock, 5.72% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NK stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to NantKwest:
|Market cap||$723.0 M||$3.0 B||$601.5 M|
|Total shares||98.4 M||99.0 M||43.9 M|
|Float shares||34.0 M||94.1 M||20.8 M|
|- Institutional holdings (%)||5.7%||86.2%||64.8%|
|- Insider holdings (%)||71.8%||0.9%||14.2%|
|Shares in short selling||0.0%||0.0%||0.0%|
|Friday, January 17th, 2020|
|Day range||$6.75 - $8.36|
|Average true range||$1.18|
|50d mov avg||$2.72|
|100d mov avg||$1.97|
|200d mov avg||$1.57|
NantKwest performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared NantKwest against Momenta Pharmaceuticals and Molecular Templates in the following table: